Fiche centre
Medical College of Wisconsin
Milwaukee — United States
Essais liés25clinical trials
VilleMilwaukeelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04259255
Essais cliniques associés
25| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Acalabrutinib | Cancer | Phase 2 | NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | ACTIVE_NOT_RECRUITING |
| Ribociclib | Cancer | Phase 3 | NCT05827081 | Adjuvant WIDER — Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | RECRUITING |
| Sonrotoclax | Cancer | Phase 3 | NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | RECRUITING |
| Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson | À vérifier | NCT04994015 | Parkinson's Foundation PD GENEration Genetic Registry | RECRUITING |
| Ozanimod | SEP | Phase 3 | NCT06408259 | Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT06337318 | Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | RECRUITING |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| Anakinra | Épilepsie | Phase 3 | NCT07281027 | COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE" | NOT_YET_RECRUITING |
| Biospecimen Collection | Cancer | Phase 3 | NCT05256225 | Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | RECRUITING |
| Edaravone (Radicava®/Radicava ORS®) | Sclérose latérale amyotrophique | À vérifier | NCT04259255 | Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS) | COMPLETED |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| AAV9-hSyn1-miGRIK2 | Épilepsie | Phase 1/2 | NCT06063850 | GenTLE — AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | RECRUITING |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04165824 | Safety Study of Oral Edaravone Administered in Subjects With ALS | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04577404 | Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED |
| CC-97540 | Myasthénie | Phase 1 | NCT06220201 | A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | ACTIVE_NOT_RECRUITING |
| Actual device PFO closure | Migraine | Non applicable | NCT04100135 | RELIEF — GORE® CARDIOFORM Septal Occluder Migraine Clinical Study | TERMINATED |
| extended release metformin | Alzheimer | Phase 2/3 | NCT04098666 | MAP — Metformin in Alzheimer's Dementia Prevention | ACTIVE_NOT_RECRUITING |
| Implant Procedure | SEP | Non applicable | NCT06796504 | The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study | RECRUITING |
| Orelabrutinib | SEP | Phase 3 | NCT07067463 | A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | RECRUITING |
| Ofatumumab approved dose | SEP | Phase 3 | NCT06869785 | FILIOS — Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab | ACTIVE_NOT_RECRUITING |
| Remibrutinib oral treatment | SEP | Phase 3 | NCT06846281 | Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | RECRUITING |
| Anti-hypertensive therapy | Hypertension | Phase 4 | NCT02299414 | Chronic Hypertension and Pregnancy (CHAP) Project | COMPLETED |
| MT-1186 | Sclérose latérale amyotrophique | Phase 3 | NCT04569084 | Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS | TERMINATED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |